Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis using the CorEvitas Psoriasis Registry
-
Published:2024-01
Issue:1
Volume:90
Page:82-90
-
ISSN:0190-9622
-
Container-title:Journal of the American Academy of Dermatology
-
language:en
-
Short-container-title:Journal of the American Academy of Dermatology
Author:
Strober BruceORCID,
Ferris Laura,
Callis Duffin Kristina,
Janak Jud C.,
Sima Adam P.,
Eckmann Thomas,
Patel Manish,
Photowala Huzefa,
Garg Vishvas,
Armstrong April
Reference10 articles.
1. Pathophysiology, clinical presentation, and treatment of psoriasis: a review;Armstrong;JAMA,2020
2. Long-term benefit-risk profiles of treatments for moderate-to-severe plaque psoriasis: a network meta-analysis;Armstrong;Dermatol Ther (Heidelb),2022
3. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials;Gordon;Lancet,2018
4. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial;Reich;Lancet,2019
5. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial;Warren;Br J Dermatol,2021
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献